Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Invivyd (IVVD)
TipRanksApr 8 12:10 ET
Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Werewolf Therapeutics (HOWL)
TipRanksSep 15, 2023 06:31 ET
HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $21 Price Target
BenzingaSep 15, 2023 06:10 ET
Nuvectis Pharma Analyst Ratings
BenzingaSep 15, 2023 06:09 ET
H.C. Wainwright Sticks to Its Buy Rating for Nuvectis Pharma (NVCT)
TipRanksMay 10, 2023 11:45 ET
H.C. Wainwright Reaffirms Their Buy Rating on Nuvectis Pharma (NVCT)
TipRanksApr 10, 2023 11:31 ET
Nuvectis Pharma (NVCT) Receives a Buy From H.C. Wainwright
TipRanksMar 7, 2023 11:37 ET
Nuvectis Pharma Analyst Ratings
Benzinga Analyst RatingsFeb 10, 2023 07:57 ET
H.C. Wainwright Keeps Their Buy Rating on Nuvectis Pharma (NVCT)
TipRanksFeb 9, 2023 12:09 ET
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Nuvectis Pharma (NVCT)
TipRanksJan 4, 2023 10:15 ET
H.C. Wainwright Reaffirms Their Buy Rating on Nuvectis Pharma (NVCT)
TipRanksSep 14, 2022 06:20 ET
H.C. Wainwright Sticks to Its Buy Rating for Nuvectis Pharma (NVCT)
TipRanksAug 5, 2022 10:50 ET
Ladenburg Thalmann Initiates Nuvectis Pharma at Buy with $21 Price Target
MT NewswiresJul 13, 2022 10:41 ET
Nuvectis Pharma Price Target Announced at $21.00/Share by Ladenburg Thalmann
Dow JonesJul 13, 2022 08:48 ET
Nuvectis Pharma Initiated at Buy by Ladenburg Thalmann
Dow JonesJul 13, 2022 08:48 ET
Nuvectis Pharma analyst ratings
Benzinga Analyst RatingsJul 13, 2022 08:38 ET
Ladenburg Thalmann Initiates Coverage On Nuvectis Pharma with Buy Rating, Announces Price Target of $21
Benzinga Real-time NewsJul 13, 2022 08:38 ET
No Data
No Data